Willow Biosciences Inc (TSE:WLLW) has released an update.
Willow Biosciences Inc. has signed a significant commercial license and royalty agreement with Kalsec Inc., set to enhance Willow’s financial position with milestone and royalty payments upon the commercialization of a new natural ingredient for savory foods. The partnership is expected to bolster Kalsec’s market share in a $200M segment, with R&D concluding in 2024 and further regulatory and scaling efforts extending into 2025. This collaboration highlights Willow’s commitment to delivering sustainable and safe natural products through its advanced biotech platforms.
For further insights into TSE:WLLW stock, check out TipRanks’ Stock Analysis page.
